Opportunities and challenges in the development of experimental drug combinations for cancer
Rachel W Humphrey1, Laura M Brockway-Lunardi, David T Bonk
1Global Development, Bristol-Myers Squibb Company, Princeton, NJ, USA.
Abstract:
It is becoming increasingly evident that cancers are dependent on a number of altered molecular pathways and can develop diverse mechanisms of resistance to therapy with single agents. Therefore, combination regimens may provide the best hope for effective therapies with durable effects. Despite preclinical data to support this notion, there are many challenges to the development of targeted combinations including scientific, economic, legal, and regulatory barriers. A discussion of these challenges and identification of models and best practices are presented with intent of aiding the research community in addressing real and perceived barriers to the development of combination therapies for cancer.
Insights
Cancer combination therapies offer durable effects against resistant tumors. However, developing these targeted treatments faces significant scientific, economic, legal, and regulatory challenges that require innovative solutions.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Therapeutics
Background:
- Cancers rely on altered molecular pathways.
- Tumors develop resistance to single-agent therapies.
- Combination regimens are promising for durable cancer treatment.
Purpose of the Study:
- To discuss challenges in developing targeted cancer combination therapies.
- To identify models and best practices for overcoming development barriers.
- To aid the research community in advancing combination therapy research.
Main Methods:
- Literature review and synthesis of existing data.
- Analysis of scientific, economic, legal, and regulatory barriers.
- Identification of best practices and development models.
Main Results:
- Preclinical data support the efficacy of combination therapies.
- Significant hurdles impede the translation of targeted combinations.
- Addressing these barriers is crucial for clinical success.
Conclusions:
- Combination therapies represent a vital strategy for effective and durable cancer treatment.
- Overcoming multifaceted challenges is essential for advancing targeted combination development.
- This work provides a framework to facilitate research in this critical area.
More Related Videos
Related Concept Videos
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:56Treatment Resistent Cancers